News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AMAG Pharmaceuticals, Inc. (AMAG) Release: Study Showing Effectiveness Of Mugard® For Management Of Oral Mucositis Featured In The Journal Cancer



4/28/2014 9:08:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass., April 28, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available today. MuGard is a mucoadhesive hydrogel that forms a protective coating over the oral mucosa. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing the mouth and throat soreness associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES